Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,750 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Severe Clear all
Not listed Phase 2Phase 3 Interventional

An Open Prospective Trial of IV Ketamine in Suicidal Adolescents

NCT02048423
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 18, 2026, 1:14 AM EDT
Completed No phase listed Observational

Imaging mGluR5 and Synaptic Density in Psychiatric Disorders

NCT03898297
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder, Healthy
Interventions
[18F]FPEB, [11C]APP311
Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Withdrawn Phase 3 Interventional

Endogenous Opioid Modulation by Ketamine

NCT03051945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine Hydrochloride, Normal saline
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Altered Calcium and Vitamin D in PMDD or Severe PMS

NCT00005119
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Measures of calcium and bone turnover
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

NCT02421965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

iCBT With TMS in Patients With MDD

NCT05988619
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Transcranial Magnetic Stimulation for Depression in Autism Spectrum Conditions

NCT05271357
View directory record Official record
Conditions
Autism Spectrum Disorder, Major Depressive Disorder
Interventions
Bilateral TMS, Unilateral TMS
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 26 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional

The RAFT ECT Study

NCT05402657
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
Procedure
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Coil Positioning in Navigated Transcranial Magnetic Stimulation Feasibility in Depression Patients Trial

NCT03795051
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Navigated Transcranial Magnetic Stimulation
Device
Lead sponsor
Magstim
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Atlanta, Georgia • Dunwoody, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Withdrawn Phase 2 Interventional

Omacor for Perimenopausal Depression

NCT00517972
View directory record Official record
Conditions
Depression
Interventions
Omacor (omega-3-acid ethyl esters)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 18, 2026, 1:14 AM EDT
Recruiting Phase 3 Interventional

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Sharmin Ghaznavi
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

NCT00931619
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Ultrasonic Brain Stimulation for Depression (R61)

NCT06902298
View directory record Official record
Conditions
Major Depressive Episode, Depression - Major Depressive Disorder, Treatment-Resistant Major Depressive Disorder
Interventions
LTFUS to SCC, LTFUS to ALIC
Device
Lead sponsor
Brian Mickey
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Pharmacotherapy of Psychotic Depression

NCT00056472
View directory record Official record
Conditions
Major Depressive Disorder With Psychotic Features
Interventions
Olanzapine, Sertraline, placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Worcester, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

NCT01742832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

NCT02372799
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Olanzapine, Fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
30
States / cities
Oceanside, California • San Marcos, California • Torrance, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

NCT00109044
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Boulder, Colorado • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Positive Processes and Transition to Health

NCT04678232
View directory record Official record
Conditions
Major Depressive Disorder, Post Traumatic Stress Disorder
Interventions
Positive Processes and Transition to Health (PATH)
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Newark, Delaware • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 18, 2026, 1:14 AM EDT